PharmaMar  
隶属西班牙Zeltia生化科技集团，20多年来致力于以海洋生物体研制新药，

PharmaMar is a Spanish member of the Zeltia Group, a leader in the development of antitumor drugs of marine origin.

The oceans cover 70% of the Earth's surface, and correspond to 90% of the biosphere. For millions of years, innumerable forms of marine life have evolved to produce an immense variety of chemical entities of exclusive sophistication. Among these, there are molecules with potent biological activities, developed as a form of biochemical warfare to survive in an extremely competitive environment. PharmaMar has identified the antitumour potential of these molecules, and is actively developing them as innovative treatments for cancer.

One of the company's commitments is to develop drugs to treat rare ("orphan") diseases, i.e. those affecting under 5 out of every 100,000 people, according to the EU's definition. PharmaMar has a strong portfolio of marine origin compounds in development

We research to provide solutions that improve the quality of life of cancer patients and their families.